 |
|
|
| |
Baseline NRTI Resistance in Suppressed Participants Did Not Lead to Viral Blips on Bictegravir/Emtricitabine/Tenofovir Alafenamide B/F/TAF or Dolutegravir DTG + F/TAF Through Week 48 in Study 380-4030
|
| |
| |
Rima K. Acosta, Hui Liu, Sean E. Collins, Hal Martin, Kirsten L. White
Gilead Sciences, Inc., Foster City, California, USA
Presented at AIDS 2020:
23rd International AIDS Conference Virtual, 6-10 July 2020
Reported by Jules Levin
|
| |
|
|
|
|
|
